Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

The global fight against Alzheimer's disease (AD) poses unique challenges for the field of
neuropsychology. Along with the increased focus on early detection of AD pathophysiology …

Introduction Automated computational assessment of neuropsychological tests would
enable widespread, cost‐effective screening for dementia. Methods A novel natural …

Background Identification of reliable, affordable, and easy-to-use strategies for detection of
dementia is sorely needed. Digital technologies, such as individual voice recordings, offer …

Due to difficulty in early diagnosis of Alzheimer's disease (AD) related to cost and
differentiated capability, it is necessary to identify low-cost, accessible, and reliable tools for …

Background: Decline in language has emerged as a new potential biomarker for the early
detection of Alzheimer's disease (AD). It remains unclear how sensitive language measures …

INTRODUCTION Identification of individuals with mild cognitive impairment (MCI) who are at
risk of develo** Alzheimer's disease (AD) is crucial for early intervention and selection of …

Alzheimer's disease (AD) is a neurodegenerative condition characterized by a gradual
decline in cognitive functions. Currently, there are no effective treatments for AD …

Voice prosody measures have been linked with Alzheimer's disease (AD), but it is unclear
whether they are associated with normal cognitive aging. We assessed relationships …

Background The global healthcare system faces increasing strain from our ageing
population, primarily due to the growing prevalence of age-related health conditions such as …